| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T243 |
0-109 |
Sentence |
denotes |
mAb name Target IgG backbone Fc modification Effect on mAb Therapy area Most advanced development stage |
| T244 |
110-214 |
Sentence |
denotes |
Andecaliximab Matrix Metalloproteinase 9 (MMP9) IgG4 S228P Stabilize core hinge Oncology Phase III |
| T245 |
215-375 |
Sentence |
denotes |
Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III |
| T246 |
376-465 |
Sentence |
denotes |
Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed |
| T247 |
466-659 |
Sentence |
denotes |
Benralizumab Interleukin 5 IgG1 Afucosylated Selectively enhance FcγRIII interaction Respiratory dermatology; ear nose throat disorders; gastrointestinal; hematology; immunology; Marketed |
| T248 |
660-789 |
Sentence |
denotes |
Durvalumab PD‐L1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2 F/G loop; plus ablate FcγR binding Oncology Marketed |
| T249 |
790-899 |
Sentence |
denotes |
Evinacumab Angiopoietin‐related protein 3 IgG4 S228P Stabilize core hinge Metabolic disorders Phase III |
| T250 |
900-1024 |
Sentence |
denotes |
Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III |
| T251 |
1025-1149 |
Sentence |
denotes |
Ixekizumab Interleukin 17A IgG4 S228P Stabilize core hinge Dermatology; immunology; musculoskeletal disorders Marketed |
| T252 |
1150-1271 |
Sentence |
denotes |
Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III |
| T253 |
1272-1428 |
Sentence |
denotes |
Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed |
| T254 |
1429-1547 |
Sentence |
denotes |
Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III |
| T255 |
1548-1638 |
Sentence |
denotes |
Nivolumab PD‐1 IgG4 S228P Stabilize core hinge Infectious disease; oncology Marketed |
| T256 |
1639-1750 |
Sentence |
denotes |
Obinutuzumab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Immunology; oncology Marketed |
| T257 |
1751-1851 |
Sentence |
denotes |
Ocaratuzumab CD20 IgG1 P247I; A339Q Selectively enhance FcγRIII interaction Oncology Phase III |
| T258 |
1852-1937 |
Sentence |
denotes |
Pembrolizumab PD‐1 IgG4 S228P Stabilize core hinge Infection; oncology Marketed |
| T259 |
1938-2054 |
Sentence |
denotes |
Roledumab Rhesus D IgG1 Afucosylated Selectively enhance FcγRIII interaction Hematological disorders Phase III |
| T260 |
2055-2167 |
Sentence |
denotes |
Spesolimab (BI‐655130) IL‐36R IgG1 L234A; L235A Ablate FcγR binding Gastrointestinal; immunology Phase III |
| T261 |
2168-2255 |
Sentence |
denotes |
Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II |
| T262 |
2256-2476 |
Sentence |
denotes |
Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III |
| T263 |
2477-2559 |
Sentence |
denotes |
Toripalimab (JS 001) PD‐1 IgG4 S228P Stabilize core hinge Oncology Phase III |
| T264 |
2560-2683 |
Sentence |
denotes |
Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III |
